Note 13 - Segments

12 Months Ended

Dec. 31, 2021

Notes to Financial Statements

Segment Reporting Disclosure [Text Block]

NOTE 13 – SEGMENTS

The Company has determined its reportable segments in accordance with ASC 280, Segment Reporting. Factors used to determine the Company’s reportable segments include the availability of separate financial statements, the existence of locally based leadership across geographic regions, the economic factors affecting each segment, and the evaluation of operating results at the segment level. The Chief Operating Decision Maker (“CODM”) allocates the Company’s resources for each of the reportable segments and evaluates their relative performance. Each reportable segment listed below has separate financial statements and locally based leadership that are evaluated based on the results of their respective segments. It should be noted that the reportable segments below have different products and services. The financial information is consolidated and evaluated regularly by the CODM in assessing performance and allocating resources.

During the third quarter of 2020, the Company considered, whether under ASC 280-10-50-3, there was a change in its reportable segments. As a result of the formation of the new Soluble subsidiary, the Company believes the Soluble business represents a reportable segment. Soluble signed its first contract during the third quarter of 2020. The Company also believes it is appropriate to combine our Skyline Medical and Skyline Europe entities into a single reportable segment based on the changes to our physical presence and intent to sign future contracts through the US entity. Finally, the Company believes the Helomics business continues to be a reportable segment.

The Company has four reportable segments: Helomics, zPREDICTA, Soluble and Skyline. See discussion of revenue recognition in Note 1 – Summary of Significant Accounting Policies for a description of the products and services recognized in each segment. The reported financial information below has been reclassified to conform to the current presentation. This information is intended to assist investors in making comparisons of the Company’s historical financial information with future financial information.

The table below summarizes the Company’s segment reporting as of and for years ended December 31, 2021 and 2020.

	Year Ended December 31, 2021
	Skyline			Helomics			Soluble			zPREDICTA			Corporate			Total
Revenue	$	1,169,811		$	13,367		$	233,293		$	90		$	4,119		$	1,420,680
Depreciation and Amortization		(30,002	)		(886,642	)		(366,713	)		(40,625	)		(16,319	)		(1,340,301	)
Impairment expense – goodwill		-			(2,813,792	)		-			-			-			(2,813,792	)
Impairment expense – intangibles		-			(2,893,548	)		-			-			-			(2,893,548	)
Impairment expense – acquired software		-			(1,249,727	)		-			-			-			(1,249,727	)
Net loss	$	(520,822	)	$	(11,326,948	)	$	(1,251,564	)	$	531,446		$	(7,089,286	)	$	(19,657,174	)

	December 31, 2021
	Skyline		Helomics		Soluble		zPREDICTA		Corporate		Total
Assets	$	906,977	$	1,802,792	$	1,742,445	$	10,782,568	$	28,536,489	$	43,771,271

	Year Ended December 31, 2020
	Skyline			Helomics			Soluble			Corporate			Total
Revenue	$	1,185,214		$	64,188		$	2,870		$	-		$	1,252,272
Depreciation and Amortization		(38,310	)		(761,105	)		(184,071	)		(41,362	)		(1,024,848	)
Impairment expense		-			(12,876,498	)		-			-			(12,876,498	)
Net loss	$	(1,132,251	)	$	(15,112,131	)	$	(671,367	)	$	(8,968,648	)	$	(25,884,397	)

	December 31, 2020
	Skyline		Helomics		Soluble		Corporate		Total
Assets	$	1,191,439	$	9,773,902	$	1,883,585	$	211,510	$	13,060,436

In 2021, substantially all the Company revenues were located or derived from operations in the United States. As of December 31, 2021, all of the Company’s long-lived assets were located within the United States.